
News|Articles|July 1, 2004
TNF inhibitor use associated with granulomatous infectious disease; infliximab poses greatest risk
Tumor necrosis factor (TNF) antagonists increase the risk of granulomatous infectious disease, including tuberculosis, according to a study-the largest of its kind to date-published in the journal Clinical Infectious Diseases. The risk of infection was 3.25-fold greater among patients who received infliximab (Remicade, Centocor) than among those who received etanercept (Enbrel, Wyeth/Amgen), the study found.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Celiac Disease and Thyroid Disease in Adolescence Linked to the Development of Type 1 Diabetes in Adulthood
2
Fulton County Leaders Discuss Closing Health Gaps and Strengthening Behavioral Health Systems
3
Consensus Guidelines for NGS in Sarcoma Diagnosis, Treatment
4
Insights from the AMCP Nexus 2025 Meeting
5

















































